Lantern Pharma Inc. has announced its financial results for the first quarter of 2025. The company reported cash, cash equivalents, and marketable securities of approximately $19.7 million as of March 31, 2025, a decrease from approximately $24.0 million at December 31, 2024. Research and development expenses were approximately $3.3 million for the quarter ended March 31, 2025, compared to approximately $4.3 million for the same period in 2024. Significant operational updates include the anticipated completion of LP-184 Phase 1a clinical trial enrollment with 62-65 patients across a range of solid tumors by the end of June 2025. Additionally, a data readout from the HARMONIC™ Trial evaluating LP-300 in never-smokers with non-small cell lung cancer is expected in Q3 2025, including initial data from the Asian expansion cohort. Lantern Pharma has also strengthened its AI intellectual property portfolio with the PCT publication of a proprietary blood-brain barrier penetration prediction patent application. The company maintains a disciplined capital management approach, providing an operating runway through at least May 15, 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.